1.Acetaminophen causes neurodevelopmental injury in susceptible babies and children: no valid rationale for controversy
Lisa ZHAO ; John P. JONES ; Lauren G. ANDERSON ; Zacharoula KONSOULA ; Cynthia D. NEVISON ; Kathryn J. REISSNER ; William PARKER
Clinical and Experimental Pediatrics 2024;67(3):126-139
Despite the worldwide acceptance of acetaminophen (APAP) as a necessary medicine in pediatrics, evidence that early exposure to APAP causes neurodevelopmental injury in susceptible babies and children has been mounting for over a decade. The evidence is diverse and includes extensive work with laboratory animals, otherwise unexplained associations, factors associated with APAP metabolism, and limited studies in humans. Although the evidence has reached an overwhelming level and was recently reviewed in detail, controversy persists. This narrative review evaluates some of that controversy. Evidence from the pre- and postpartum periods was considered to avoid controversy raised by consideration of only limited evidence of risks during the prepartum period. Among other issues, the association between APAP use and the prevalence of neurodevelopmental disorders was considered. A systematic review revealed that the use of APAP in the pediatric population was never tracked carefully; however, historical events that affected its use were documented and are sufficient to establish apparent correlations with changes in the prevalence of neurodevelopmental disorders. Moreover, problems with the exclusive reliance on results of meta-analyses of large datasets with limited time frames of drug exposure were reviewed. Furthermore, the evidence of why some children are susceptible to APAPinduced neurodevelopmental injuries was examined. We concluded that available evidence demonstrates that early exposure to APAP causes neurodevelopmental injury in susceptible babies and small children.
2.Acetaminophen causes neurodevelopmental injury in susceptible babies and children: no valid rationale for controversy
Lisa ZHAO ; John P. JONES ; Lauren G. ANDERSON ; Zacharoula KONSOULA ; Cynthia D. NEVISON ; Kathryn J. REISSNER ; William PARKER
Clinical and Experimental Pediatrics 2024;67(3):126-139
Despite the worldwide acceptance of acetaminophen (APAP) as a necessary medicine in pediatrics, evidence that early exposure to APAP causes neurodevelopmental injury in susceptible babies and children has been mounting for over a decade. The evidence is diverse and includes extensive work with laboratory animals, otherwise unexplained associations, factors associated with APAP metabolism, and limited studies in humans. Although the evidence has reached an overwhelming level and was recently reviewed in detail, controversy persists. This narrative review evaluates some of that controversy. Evidence from the pre- and postpartum periods was considered to avoid controversy raised by consideration of only limited evidence of risks during the prepartum period. Among other issues, the association between APAP use and the prevalence of neurodevelopmental disorders was considered. A systematic review revealed that the use of APAP in the pediatric population was never tracked carefully; however, historical events that affected its use were documented and are sufficient to establish apparent correlations with changes in the prevalence of neurodevelopmental disorders. Moreover, problems with the exclusive reliance on results of meta-analyses of large datasets with limited time frames of drug exposure were reviewed. Furthermore, the evidence of why some children are susceptible to APAPinduced neurodevelopmental injuries was examined. We concluded that available evidence demonstrates that early exposure to APAP causes neurodevelopmental injury in susceptible babies and small children.
3.Acetaminophen causes neurodevelopmental injury in susceptible babies and children: no valid rationale for controversy
Lisa ZHAO ; John P. JONES ; Lauren G. ANDERSON ; Zacharoula KONSOULA ; Cynthia D. NEVISON ; Kathryn J. REISSNER ; William PARKER
Clinical and Experimental Pediatrics 2024;67(3):126-139
Despite the worldwide acceptance of acetaminophen (APAP) as a necessary medicine in pediatrics, evidence that early exposure to APAP causes neurodevelopmental injury in susceptible babies and children has been mounting for over a decade. The evidence is diverse and includes extensive work with laboratory animals, otherwise unexplained associations, factors associated with APAP metabolism, and limited studies in humans. Although the evidence has reached an overwhelming level and was recently reviewed in detail, controversy persists. This narrative review evaluates some of that controversy. Evidence from the pre- and postpartum periods was considered to avoid controversy raised by consideration of only limited evidence of risks during the prepartum period. Among other issues, the association between APAP use and the prevalence of neurodevelopmental disorders was considered. A systematic review revealed that the use of APAP in the pediatric population was never tracked carefully; however, historical events that affected its use were documented and are sufficient to establish apparent correlations with changes in the prevalence of neurodevelopmental disorders. Moreover, problems with the exclusive reliance on results of meta-analyses of large datasets with limited time frames of drug exposure were reviewed. Furthermore, the evidence of why some children are susceptible to APAPinduced neurodevelopmental injuries was examined. We concluded that available evidence demonstrates that early exposure to APAP causes neurodevelopmental injury in susceptible babies and small children.
4.Acetaminophen causes neurodevelopmental injury in susceptible babies and children: no valid rationale for controversy
Lisa ZHAO ; John P. JONES ; Lauren G. ANDERSON ; Zacharoula KONSOULA ; Cynthia D. NEVISON ; Kathryn J. REISSNER ; William PARKER
Clinical and Experimental Pediatrics 2024;67(3):126-139
Despite the worldwide acceptance of acetaminophen (APAP) as a necessary medicine in pediatrics, evidence that early exposure to APAP causes neurodevelopmental injury in susceptible babies and children has been mounting for over a decade. The evidence is diverse and includes extensive work with laboratory animals, otherwise unexplained associations, factors associated with APAP metabolism, and limited studies in humans. Although the evidence has reached an overwhelming level and was recently reviewed in detail, controversy persists. This narrative review evaluates some of that controversy. Evidence from the pre- and postpartum periods was considered to avoid controversy raised by consideration of only limited evidence of risks during the prepartum period. Among other issues, the association between APAP use and the prevalence of neurodevelopmental disorders was considered. A systematic review revealed that the use of APAP in the pediatric population was never tracked carefully; however, historical events that affected its use were documented and are sufficient to establish apparent correlations with changes in the prevalence of neurodevelopmental disorders. Moreover, problems with the exclusive reliance on results of meta-analyses of large datasets with limited time frames of drug exposure were reviewed. Furthermore, the evidence of why some children are susceptible to APAPinduced neurodevelopmental injuries was examined. We concluded that available evidence demonstrates that early exposure to APAP causes neurodevelopmental injury in susceptible babies and small children.
5.Effects of nursing interventions based on SMART principle in patients with chronic urticaria
Dan LIU ; Wanshu FENG ; Zhaohui WANG ; Liu FENG ; Beibei TIAN ; Lisa ZHAO
Chinese Journal of Modern Nursing 2023;29(19):2616-2620
Objective:To explore the effects of nursing interventions based on SMART (specific, measurable, attainable, relevant, and time-based) principle in patients with chronic urticaria.Methods:From January 2021 to January 2022, convenience sampling was used to select 128 patients with chronic urticaria admitted to the allergy department of Henan Provincial People's Hospital as the study subject. The patients were divided into control group and observation group using a random number table method, with 64 cases in each group. The control group received routine nursing, while the observation group received nursing interventions based on SMART principle for three months. The Rating Scale of Health Self-management Skill for Adults, Life Event Scale, and Trait Coping Style Questionnaire were used to measure patients before and three months after intervention, and short-term efficacy was evaluated.Results:The total short-term curative effective rate of the observation group was 82.81% (53/64), while the control group was 65.63% (42/64) ; the recurrent interval time in the observation group was (30.29±7.35) days, while in the control group it was (21.63±7.46) days; and the differences were statistically significant ( P<0.05). After intervention, the scores of the self-management behavior, self-management cognition, self-management environment, and the total score of Rating Scale of Health Self-management Skill for Adults in the observation group were higher than those in the control group, and the differences were statistically significant ( P<0.05). After intervention, the scores of positive event stimulus in Life Event Scale and positive coping in Trait Coping Style Questionnaire in the observation group were higher than those in the control group, while the scores of negative event stimulus and negative coping were lower than those in the control group, with statistically significant differences ( P<0.05) . Conclusions:Nursing interventions based on the SMART principle can effectively improve the short-term curative efficacy and the self-management ability of patients with chronic urticaria, and change their physiological and social stress levels and coping styles.
6.Prognostic Significance of Follicular Lymphoma International Prognostic Index 2 (FLIPI2) in Follicular Lymphoma Patients Treated with Rituximab Maintenance.
Peng-Peng XU ; Ying QIAN ; Qiu-Sheng CHEN ; Liang-Qun LI ; Li ZHANG ; Wei-Li ZHAO
Journal of Experimental Hematology 2017;25(2):426-430
OBJECTIVETo investigate the prognostic significance of Follicular Lymphoma International Prognostic Index 2 (FLIPI2) in FL patients treated with rituximab maintenance.
METHODSA tatol of 140 newly diagnosed FL patients who received Rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) chemotherapy in our department were retrospectively analyzed from December 2002 to December 2014. Among 140 patients with FL 122 patients achieved response, from them 56 patients received R maintenance (RM) every 2 months for median 8 times (RM group) while the rest 66 patients did not receive further anti-lymphoma treatment (non-RM group).
RESULTSThere was no statistical difference in age, sex, pathologic grading, staging, FLIPI or FLIPI2 between RM and non-RM groups. The 2-year progression-free survival (PFS) of RM and non-RM groups were 89.7% and 77.6% (P=0.043) while the 2-year overall survival were 100% and 98.6% (P=0.131). FLIPI2 is a significant prognostic model either in the total cohort, RM or non-RM groups (P<0.001 all). In subgroup analysis, RM was able to decrease disease progression in low and intermediate-risk group of FLIPI2, while the 2-year PFS of RM and non-RM groups in high-risk group were similar (55.6% vs 46.9%)(P=0.920).
CONCLUSIONFLIPI2 presents robust prognostic significance either in RM or OBS patients, the patients in FLIPI2 low and intermediate-risk group may benefite from RM, but the role of RM in high-risk patients should be further to investigate.
7.Urgent need to improve the quality of case report in traditional Chinese medicine: Assessment on reporting quality of 3,417 cases.
Shu-Fei FU ; Wai KUN ; Xiao-Xi ZENG ; Li ZHANG ; Chung-Wah CHENG ; Lisa SONG ; Linda Li-Dan ZHONG ; Jia LIN ; Yong-Yan WANG ; Hong-Cai SHANG ; Zhao-Xia BIAN ; null
Chinese journal of integrative medicine 2016;22(6):473-480
OBJECTIVETo survey the reporting quality of traditional Chinese medicine (TCM) case reports published in recent years and understand the common problems. The assessment results would lay the foundation for the development of recommendations for case report in Chinese medicine.
METHODSThis survey determined the reporting quality of cases with Chinese herbal decoction, Chinese proprietary medicine, acupuncture, moxibustion and other traditional therapies published in 20 core medical journals of China by searching the China Academic Journals Full-text Database from 2006 to 2010. Fifty survey items in 16 domains were used to determine the reporting quality. One point was assigned to each item (Yes=1 point; No=0 point), and total score was 50 points. The domain of treatment was assessed independently, ranging from 2 to 9 items for different TCM interventions.
RESULTSThe total of 1,858 case reports, covering 3,417 cases were included to analyze from 13 out of 20 core medical journals of China. There were 74.8% of them did not identify the nature of study in title, while 73.9% did not comprise an abstract. Incomplete reporting was found in discussions/ comment, and only 38.9% had made recommendations or take-away messages. Figures and tables were infrequently used. Three cases cited the full names of patients, but without declaring that any consent was obtained. Over 90% reported the symptoms and signs of TCM, and characteristics on tongue and pulse, but less than 50% did mention other medical history and diagnostic rationale. More than 90% treatments of the included cases were herbal decoction, with clear reporting on the ingredients and dosages. However, the reporting rate of the dosages of each ingredient was just 48.4%. Almost none reported the quality control of crude herbs, manufacturers and lot numbers of herbal proprietary medicine. Besides, advices and precautions on diet, emotions and living were rare to be illustrated.
CONCLUSIONSystematic reporting recommendations are urged to develop for improving the contents and format of case reports in TCM.
Humans ; Medicine, Chinese Traditional ; Outcome Assessment (Health Care) ; Periodicals as Topic ; Quality Assurance, Health Care ; Research Report ; standards